Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Lipitor versus Atorvastatin Sandoz 40 mg in healthy Thai volunteers under fasting conditions
TCTR20190902003Phase 1Not yet recruiting
- Sponsor
- Novartis
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of atorvastatin in hypercholesterolemia and dyslipidemia (2 arms), sponsored by Novartis. Primary endpoints: AUC0-t of atorvastatin, AUC0-inf of atorvastatin and 4 more. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
atorvastatin
03
Conditions
hypercholesterolemiadyslipidemia
Beyond the preview
Go deeper on TCTR20190902003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190902003.